公开(公告)号：EP2120566B1

公开(公告)日：2019-05-08

申请号：EP07872645.2

申请日：2007-12-28

Applicant: Idenix Pharmaceuticals LLC ,  Centre National de la Recherche Scientifique ,  Université de Montpellier

Inventor： SOMMADOSSI, Jean-Pierre ,  GOSSELIN, Gilles ,  PIERRA, Claire ,  PERIGAUD, Christian ,  PEYROTTES, Suzanne

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/04 ,  C07H19/10 ,  C07H19/20 ,  C07H19/048 ,  C07F9/6558 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  C07H19/00 ,  A61K31/7076 ,  A61K31/708 ,  C07F9/6561

公开(公告)号：EP2506711B1

公开(公告)日：2019-04-03

申请号：EP10834963.0

申请日：2010-11-23

Applicant: OPKO Health, Inc.

Inventor： AHMED, Tahir

IPC: A01N43/04 ,  A61K31/715 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P29/00

公开(公告)号：EP1432312B1

公开(公告)日：2019-01-09

申请号：EP02770446.9

申请日：2002-08-29

Applicant: Orthopeutics, LP

Inventor： HEDMAN, Thomas, P.

IPC: A01N43/04 ,  A61K31/70

公开(公告)号：EP3337321A1

公开(公告)日：2018-06-27

申请号：EP16837913.9

申请日：2016-08-19

Applicant: President and Fellows of Harvard College

Inventor： OH, Sungwhan ,  ERTURK-HASDEMIR, Deniz ,  KASPER, Dennis, L.

IPC: A01N43/04 ,  A61K31/715

CPC classification number: A61K31/739

Abstract: The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof.

公开(公告)号：EP3142643A4

公开(公告)日：2018-01-10

申请号：EP15791964

申请日：2015-05-15

Applicant: INSMED INCORPORATED

Inventor： EAGLE GINA ,  GUPTA RENU

IPC: A61K9/127 ,  A01N43/04

CPC classification number: A61K31/7036 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0078 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：EP3261440A1

公开(公告)日：2018-01-03

申请号：EP16753229.0

申请日：2016-02-22

Applicant: University of Iowa Research Foundation ,  Fondazione Telethon

Inventor： DAVIDSON, Beverly, L. ,  CHEN, Yong Hong ,  AURICCHIO, Alberto

IPC: A01N43/04 ,  A01N63/00 ,  A01N65/00 ,  A61K48/00 ,  C12N15/63 ,  C12N15/85

CPC classification number: C12N15/8616 ,  A61K48/0008 ,  A61K48/0058 ,  A61P27/00 ,  C07K14/005 ,  C12N15/86 ,  C12N2750/14122 ,  C12N2750/14145 ,  C12N2810/50

Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targetting peptides that deliver agents, to the eye. The present inventors have discovered peptides that function to target agents, such as viral vectors, to ocular cells. The present disclosure describes a method to utilize these novel peptides to direct, for example, viral capsids to the cell type of interest. In this instance, ocular cells (such as retinal cells) are targeted by the identified peptides. Vectors harboring capsid proteins modified to include such peptides can be used to provide therapeutic agents to the eye.

公开(公告)号：EP3249052A1

公开(公告)日：2017-11-29

申请号：EP17162101.4

申请日：2007-05-10

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： TAN, Pamela ,  BRAMLAGE, Birgit ,  FRANK-KAMENETSKY, Maria ,  FITZGERALD, Kevin ,  AKINC, Akin ,  KOTELIANSKI, Victor E.

IPC: C12Q1/68 ,  A01N43/04 ,  C07H21/04 ,  A61K31/07 ,  C12N15/113

CPC classification number: C12N15/1137 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/332 ,  C12N2310/3515 ,  C12N2310/3521

Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition.

Abstract translation: 本发明涉及用于抑制PCSK9基因（PCSK9基因）表达的双链核糖核酸（dsRNA），其包含具有长度小于30个核苷酸，通常长度为19-25个核苷酸的核苷酸序列的反义链 并且其与PCSK9基因的至少一部分基本上互补。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物; 使用该药物组合物治疗由PCSK9基因表达引起的疾病和PCSK9基因表达的方法。

公开(公告)号：EP2120568B1

公开(公告)日：2017-11-15

申请号：EP08730048.9

申请日：2008-02-15

Applicant: Celator Pharmaceuticals, Inc.

Inventor： LOUIE, Arthur ,  SWENSON, Christine ,  MAYER, Lawrence ,  JANOFF, Andrew

IPC: A01N43/04 ,  A61K31/70 ,  A61K9/127 ,  A61K9/00

CPC classification number: A61K31/70 ,  A61K9/0019 ,  A61K9/127 ,  Y10T436/143333

公开(公告)号：EP3190886A1

公开(公告)日：2017-07-19

申请号：EP15840207.3

申请日：2015-09-11

Applicant: Synedgen, Inc.

Inventor： BAKER, Shenda ,  WIESMANN, William, P. ,  TOWNSEND, Stacy, Marie

IPC: A01N43/04

CPC classification number: A61K31/726 ,  A61K9/0078 ,  A61K9/08 ,  A61K9/14 ,  A61K9/48 ,  A61K45/06 ,  A61K47/10

Abstract: Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.

Abstract translation: 本文描述了用于治疗或预防受试者的肺系统（例如囊性纤维化），呼吸系统或消化系统的疾病或病症的方法，所述方法包括施用包含水溶性聚葡糖胺和衍生化聚葡糖胺的化合物或组合物。

公开(公告)号：EP2552203B1

公开(公告)日：2017-03-22

申请号：EP11763405.5

申请日：2011-03-31

Applicant: Idenix Pharmaceuticals LLC ,  Centre National de la Recherche Scientifique

Inventor： SURLERAUX, Dominique ,  GOSSELIN, Gilles

IPC: C07H19/20 ,  A61K31/70 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A01N43/04 ,  A61K31/7056 ,  A61K31/708 ,  A61K31/7105 ,  A61K31/713 ,  C07H17/02 ,  C07H19/10 ,  C07F9/24 ,  A61P31/12 ,  A61P31/14

CPC classification number: C07H17/02 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7105 ,  A61K31/713 ,  C07F9/24 ,  C07H19/10 ,  C07H19/20